Thermo fisher scientific announces fda approval of oncomine dx target test as the first ngs-based companion diagnostic to aid in therapy selection for patients with ret mutations/fusions in thyroid cancers

Carlsbad, calif.--(business wire)--the u.s. food and drug administration (fda) has granted approval to thermo fisher scientific's oncomine dx target test as a companion diagnostic (cdx) to aid in selection of patients with ret-fusion positive locally advanced or metastatic non-small cell lung cancer (nsclc), ret-fusion positive advanced or metastatic thyroid cancer and ret-mutation positive advanced or metastatic medullary thyroid cancer (mtc) who may be eligible for treatment with lilly's rete
TMO Ratings Summary
TMO Quant Ranking